For EGFR-driven NSCLC, nanocarrier-assisted PROTAC delivery significantly enhanced in vivo antitumor efficacy in resistant xenografts, while co-delivery of EGFR and BRD4 degraders in a single nanoplatform achieved synergistic tumor suppression [189,190]. The gene discussed is BRD4; the disease is neoplasm.